Rapamycin, a drug used by organ transplant and cancer patients, appears to interact with the Yin Yang 1 gene and disrupt the insulin-signaling pathway in the liver and muscles, which results in the onset of diabetes in mice, researchers reported in Cell Metabolism. The findings suggest that rapamycin-treated patients may also want to take antidiabetes drugs that boost insulin sensitivity.

Related Summaries